Question
A 67-year-old lady attends clinic complaining of involuntary urine leakage. Over the past 10 months, she notices urine escapes especially when she laughs, coughs, or sneezes. She does not typically experience urgency or difficulty reaching the toilet in time.
She has a history of dyslipidaemia and takes rosuvastatin. She has had three normal vaginal deliveries. Her BMI is 30 kg/m².
She has been diligently performing pelvic floor strengthening exercises for 5 months but reports no improvement. She is not keen on undergoing surgery.
What is the most appropriate next management step?
A. Retropubic suspension surgery
B. Beta-3 agonist therapy
C. Serotonin-noradrenaline reuptake inhibitor therapy
D. Anticholinergic bladder relaxant
E. Bladder training programme
Answer
C. Serotonin-noradrenaline reuptake inhibitor therapy (Duloxetine)
Detailed discussion for MRCP
This is a classic stress urinary incontinence (SUI) scenario.
Step 1: Identify the type of incontinence
Key clinical clue:
- Leakage with coughing, sneezing, laughing → ↑ intra-abdominal pressure → SUI
No urgency → excludes urge incontinence
No continuous dribbling → excludes overflow
Step 2: Risk factors present
This patient has multiple strong risk factors:
- Female sex
- Increasing age
- Vaginal deliveries (pelvic floor weakness)
- Elevated BMI
- Likely estrogen deficiency (post-menopause)
Step 3: Standard management pathway (VERY IMPORTANT FOR MRCP)
First-line
- Pelvic floor muscle training (PFMT)
- ≥3 months minimum
- Supervised preferred
This patient has already completed adequate PFMT → failed
Step 4: Next step depends on patient preference
Option 1: Surgery (definitive)
- Mid-urethral sling (gold standard)
- Colposuspension
BUT → patient declines surgery
Step 5: Non-surgical pharmacological option
Duloxetine
- SNRI
- Increases urethral sphincter tone via:
- ↑ serotonin + noradrenaline in pudendal nerve
- ↑ external urethral sphincter contraction
👉 Indication:
- Moderate–severe SUI
- Failed PFMT
- Patient declines surgery
Step 6: Why other options are wrong
A. Colposuspension
- Surgical → patient refuses
B. Mirabegron
- Used for urge incontinence (OAB)
- Not useful in SUI
D. Oxybutynin / Tolterodine
- Antimuscarinics → treat detrusor overactivity
- Again urge incontinence, not stress
E. Bladder training
- Used in urge incontinence
High-yield MRCP Concepts
Types of urinary incontinence
| Type | Mechanism | Key symptom |
|---|---|---|
| Stress | Urethral sphincter weakness | Leak on cough/sneeze |
| Urge | Detrusor overactivity | Sudden urgency |
| Overflow | Obstruction/underactive bladder | Dribbling |
| Functional | Mobility/cognition issues | Can’t reach toilet |
Key NICE exam points
- PFMT = first-line for SUI
- Antimuscarinics = first-line for urge
- Duloxetine = ONLY drug for SUI
- Surgery = definitive for SUI
Important clinical pearls
- Duloxetine is NOT first-line
- Used only when:
- PFMT fails
- Surgery declined
- Side effects:
- Nausea (very common → exam favorite)
- Fatigue
- Dry mouth
Cheat Sheet
- Leak on cough → stress incontinence
- First step → pelvic floor exercises (3 months minimum)
- Failed PFMT + refuses surgery → duloxetine
- Urge incontinence → antimuscarinics / mirabegron
- Surgery = definitive treatment
Flash Cards
Q: What is the hallmark symptom of stress urinary incontinence?
A: Leakage during increased intra-abdominal pressure (cough, sneeze).
Explanation: Due to urethral sphincter weakness.
Q: First-line treatment for stress incontinence?
A: Pelvic floor muscle training.
Explanation: Strengthens urethral support.
Q: Drug used in stress incontinence?
A: Duloxetine.
Explanation: SNRI increases urethral sphincter tone.
Q: First-line drugs for urge incontinence?
A: Antimuscarinics (e.g., oxybutynin).
Explanation: Reduce detrusor overactivity.
Q: Mechanism of duloxetine in SUI?
A: Enhances pudendal nerve activity → increases sphincter contraction.
Q: When is surgery indicated in SUI?
A: Failed conservative therapy + patient consents.
MCQs to test yourself
1. A 62-year-old woman leaks urine when coughing. She completed 4 months of pelvic exercises without improvement and refuses surgery. Best treatment?
A. Tolterodine
B. Mirabegron
C. Duloxetine
D. Desmopressin
E. Bladder retraining
Answer: C
Explanation: Classic SUI → failed PFMT → duloxetine if surgery declined.
2. Which of the following is FALSE regarding stress incontinence?
A. Caused by detrusor overactivity
B. Associated with vaginal delivery
C. Managed initially with pelvic floor exercises
D. Can be treated with duloxetine
E. Surgery is definitive
Answer: A
Explanation: Stress incontinence is due to sphincter weakness, not detrusor overactivity.
3. A drug that works by increasing urethral sphincter tone is:
A. Oxybutynin
B. Duloxetine
C. Mirabegron
D. Tolterodine
E. Solifenacin
Answer: B
Explanation: Duloxetine increases serotonin/noradrenaline → sphincter contraction.
4. Mirabegron is indicated in:
A. Stress incontinence
B. Overflow incontinence
C. Urge incontinence
D. Functional incontinence
E. Mixed incontinence only
Answer: C
Explanation: Beta-3 agonist → relaxes detrusor muscle.
5. Which is the most definitive treatment for stress incontinence?
A. Duloxetine
B. Bladder retraining
C. Antimuscarinics
D. Mid-urethral sling
E. Desmopressin
Answer: D
Explanation: Surgery provides definitive cure.
6. Which side effect is most commonly associated with duloxetine?
A. Hypertension
B. Bradycardia
C. Nausea
D. Hyperkalemia
E. Weight gain
Answer: C
Explanation: Nausea is very common → exam favorite.
Summary for quick exam revision
Stress urinary incontinence presents with leakage during increased intra-abdominal pressure and is strongly associated with age, obesity, and vaginal delivery; first-line treatment is pelvic floor muscle training for at least 3 months, and if this fails and the patient declines surgery, duloxetine (an SNRI that increases urethral sphincter tone) is the appropriate next step, whereas antimuscarinics and mirabegron are reserved for urge incontinence.